|

A Study of GR1803 in Systemic Lupus Erythematosus

RECRUITINGPhase 1/2Sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Actively Recruiting
PhasePhase 1/2
SponsorGenrix (Shanghai) Biopharmaceutical Co., Ltd.
Started2025-12-31
Est. completion2027-06-01
Eligibility
Age18 Years – 60 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07348055

Summary

to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus

Eligibility

Age: 18 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

* comfirmed diagnosis of systemic lupus erythematosus
* SLEDAI-2K≥6分
* written informed consent and ability to comply with protocol requirements
* have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months

Exclusion Criteria:

* with unstable acute and chronic diseases
* active infection
* history of malignant tumor within 5 years

Conditions3

Auto Immune DiseaseLupusSystemic Lupus Erthematosus

Browse More Trials

Lupus trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.